| Amine functionalization via oxidative photoredox catalysis: methodology development and complex molecule synthesis JW Beatty, CRJ Stephenson Accounts of Chemical Research 48 (5), 1474-1484, 2015 | 622 | 2015 |
| A scalable and operationally simple radical trifluoromethylation JW Beatty, JJ Douglas, KP Cole, CRJ Stephenson Nature communications 6 (1), 7919, 2015 | 358 | 2015 |
| Photochemical perfluoroalkylation with pyridine N-oxides: mechanistic insights and performance on a kilogram scale JW Beatty, JJ Douglas, R Miller, RC McAtee, KP Cole, CRJ Stephenson Chem 1 (3), 456-472, 2016 | 227 | 2016 |
| Synthesis of (−)-pseudotabersonine,(−)-pseudovincadifformine, and (+)-coronaridine enabled by photoredox catalysis in flow JW Beatty, CRJ Stephenson Journal of the American Chemical Society 136 (29), 10270-10273, 2014 | 165 | 2014 |
| Visible light-mediated decarboxylative alkylation of pharmaceutically relevant heterocycles AC Sun, EJ McClain, JW Beatty, CRJ Stephenson Organic letters 20 (12), 3487-3490, 2018 | 92 | 2018 |
| Design and implementation of a catalytic electron donor–acceptor complex platform for radical trifluoromethylation and alkylation EJ McClain, TM Monos, M Mori, JW Beatty, CRJ Stephenson ACS Catalysis 10 (21), 12636-12641, 2020 | 83 | 2020 |
| Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth G Andriani, E Amata, J Beatty, Z Clements, BJ Coffey, G Courtemanche, ... Journal of medicinal chemistry 56 (6), 2556-2567, 2013 | 74 | 2013 |
| Radical chlorodifluoromethylation: providing a motif for (hetero) arene diversification RC McAtee, JW Beatty, CC McAtee, CRJ Stephenson Organic letters 20 (12), 3491-3495, 2018 | 60 | 2018 |
| Discovery of potent and selective non-nucleotide small molecule inhibitors of CD73 JW Beatty, EA Lindsey, R Thomas-Tran, L Debien, D Mandal, JL Jeffrey, ... Journal of medicinal chemistry 63 (8), 3935-3955, 2020 | 40 | 2020 |
| Discovery of potent and selective PI3Kγ inhibitors SL Drew, R Thomas-Tran, JW Beatty, J Fournier, KV Lawson, DH Miles, ... Journal of Medicinal Chemistry 63 (19), 11235-11257, 2020 | 32 | 2020 |
| Azolopyrimidine for the treatment of cancer-related disorders J Beatty, L Debien, J Jeffrey, MR Leleti, D Mandal, D Miles, J Powers, ... US Patent 10,399,962, 2019 | 10 | 2019 |
| Design, synthesis, and structure–activity relationship optimization of pyrazolopyrimidine amide inhibitors of phosphoinositide 3-kinase γ (PI3Kγ) G Mata, DH Miles, SL Drew, J Fournier, KV Lawson, AK Mailyan, ... Journal of Medicinal Chemistry 65 (2), 1418-1444, 2021 | 9 | 2021 |
| Azolopyrimidine for the treatment of cancer-related disorders J Beatty, L Debien, J Jeffrey, MR Leleti, D Mandal, D Miles, J Powers, ... | 3 | 2018 |
| Inhibitors of hif-2alpha JW Beatty, SL Drew, JTA Fournier, T Guney, SD Jacob, KV Lawson, ... US Patent App. 17/777,103, 2023 | 1 | 2023 |
| Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α JW Beatty, SL Drew, M Epplin, JTA Fournier, GAL Balint, T Guney, ... US Patent 11,407,712, 2022 | 1 | 2022 |
| Abstract P206: AB521 potently and selectively inhibits pro-tumorigenic gene transcription by Hypoxia-Inducible Factor (HIF)-2α in vitro and in vivo KES Gauthier, D Piovesan, S Cho, KV Lawson, PG Schweickert, A Lopez, ... Molecular Cancer Therapeutics 20 (12_Supplement), P206-P206, 2021 | 1 | 2021 |
| Discovery and characterization of AB521, a novel, potent, and selective hypoxia-inducible factor (HIF)-2α inhibitor KV Lawson, KES Gauthier, AK Mailyan, JT Fournier, JW Beatty, SL Drew, ... Cancer Res. 81, 1206, 2021 | 1 | 2021 |
| 2, 3, 5-trisubstituted pyrazolo [1, 5-a] pyrimidine compounds JW BEATTY, SL DREW, JTA FOURNIER, JL JEFFREY, KV LAWSON, ... | 1 | 2020 |
| Reversal of adenosine-mediated immune suppression by AB421, a potent and selective small-molecule CD73 inhibitor JBL Tan, A Becker, D DiRenzo, K Zhang, A Chen, R Thomas-Tran, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017 | 1 | 2017 |
| Redox Activation of C–C and C–H Bonds Using Visible Light. JW Beatty | 1 | 2016 |
